Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Stem Cells. 2018 Jan 10;36(3):446–457. doi: 10.1002/stem.2760

Figure 6. Depletion of IL-11 in lethally irradiated recipients ameliorates the engraftment defect of Vav1−/− HSPCs.

Figure 6

A) Schema of the experimental design for transplantation studies shown in B) and C). Lethally irradiated recipients were treated with an IL-11 blocking antibody or an IgG isotype control, and transplanted with BM cells from WT or Vav1−/− mice. IL-11 blocking antibody or isotype control were injected 6 and 24 h after irradiation at the dose of 1 mg/Kg of body weight. B) Overall survival of lethally irradiated recipients treated with IgG or an IL-11 blocking antibody and transplanted with WT or Vav1−/− adult HSPCs. C) Analysis of mice in the 4 cohorts of the study. Engraftment of WT or Vav1−/− HSPCs into lethally irradiated syngeneic recipients treated with an IL-11 blocking antibody or an isotype control was evaluated by % of donor-derived PB cells 6 weeks after transplantation. Table indicates the median percentage of chimerism in surviving mice at the indicated time point.